Literature DB >> 4045562

Melanoma localization in nude mice with monoclonal Fab against p97.

P L Beaumier, K A Krohn, J A Carrasquillo, J Eary, I Hellström, K E Hellström, W B Nelp, S M Larson.   

Abstract

The tumor targeting capacity of monoclonal antibody Fab fragments was explored in nude mice bearing human melanoma xenografts. Radioiodinated Fab 8.2 and 96.5, specific for melanoma-associated antigen p97, were tested in vitro for immunoreactivity and in vivo for tumor localization relative to a co-administered control, Fab 1.4. Fab was cleared rapidly from the blood with a T1/2 of 3-3.5 hr and greater than 90% of the injected radioactivity was excreted by 16 hr. The mean specific Fab in tumor reached a maximum of 3.5% injected dose/g at 4 hr and decreased to 1.5% at 16 hr. Over the same period, the ratio of specific/control Fab in tumor normalized to blood, the localization index, rose from 3 to 25 compared with ratios near unity for all other tissues. The concentration of specific Fab in tumor could be correlated to the amount of Fab protein administered as well as its immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045562

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Alterations in an indium-111 Fab' under conditions of utilization.

Authors:  S E Halpern; J P Tarburton; E Sudora; P Hagan
Journal:  Eur J Nucl Med       Date:  1992

2.  A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells.

Authors:  K Z Walker; K Seymour-Munn; F K Keech; S M Axiak; G J Bautovich; J G Morris; A Basten
Journal:  Eur J Nucl Med       Date:  1986

3.  Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

Authors:  N Watanabe; N Oriuchi; S Sugiyama; M Kuroki; Y Matsuoka
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

4.  Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.

Authors:  Ann-Charlott Steffen; Anna Orlova; Maria Wikman; Fredrik Y Nilsson; Stefan Ståhl; Gregory P Adams; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

5.  Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts.

Authors:  S M Andrew; M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1986

6.  Application of lectins to tumor imaging radiopharmaceuticals.

Authors:  S Kojima; M Jay
Journal:  Eur J Nucl Med       Date:  1986

7.  Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose.

Authors:  S Duewell; W Horst; G Westera
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Authors:  G P Adams; R Schier; A M McCall; R S Crawford; E J Wolf; L M Weiner; J D Marks
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface.

Authors:  H J Garrigues; M W Lark; S Lara; I Hellström; K E Hellström; T N Wight
Journal:  J Cell Biol       Date:  1986-11       Impact factor: 10.539

10.  Development and characterization of chimeric anti-carcinoembryonic antigen monoclonal antibodies and their Fab fragments.

Authors:  T Kamigaki; H Ohyanagi; M Yamamoto; T Kaneda; T Goto; T Ohmura; K Yokoyama; Y Saitoh
Journal:  Jpn J Cancer Res       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.